Fisher Wallace Laboratories,

Fisher Wallace Labs is on a mission to vastly increase access to mental healthcare. We develop and commercialize wearable brain stimulation technology for the treatment of depression, anxiety, and other neuropsychiatric and cognitive disorders. Our technology was recently proven to be rapidly effective in two large clinical trials for the treatment of Major Depressive Disorder and Generalized Anxiety Disorder, the latter of which was conducted in collaboration with the Seattle Police Department and Washington State University. Previous research includes a successful pilot study conducted at Beth Israel Hospital for the treatment of Bipolar II Depression, and a substance use rehabilitation study conducted at Phoenix House. Under temporary FDA clearance, we distributed 100,000 Version 1.0 devices through 14,000 prescribers, generating $40 million in revenue, and obtained Medicaid reimbursement in Maine (MaineCare). We are currently engaged in obtaining regulatory approval for OAK, our Version 2.0 technology, designed in collaboration with the teams behind Beats and Nest, with the goal of commercializing in 2025 and ultimately achieving smartphone scale.